GI Oncology
News
MicroRNA-375 may be key to fibrolamellar carcinoma
Overexpression of microRNA-375 in a fibrolamellar carcinoma cell line suppressed cell migration and proliferation, which hints at therapeutic...
Conference Coverage
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
From the Journals
Study eyes biomarkers of regorafenib response in hepatocellular carcinoma
Among 266 proteins tested, decreased levels of 5 correlated with significantly longer overall survival on regorafenib therapy.
From the Journals
Distinct features found in young-onset CRC
Unique biological subtypes in young patients may affect how their cancers behave and may require a personalized approach to treatment.
Conference Coverage
Survey: CRC diagnosis often delayed or initially missed in patients under age 50
Over half of young CRC patients responding to a survey had at least three symptoms and still waited at least 3 months before visiting a doctor.
From the Journals
Interactive online module improved detection of Barrett’s esophagus neoplasia
Median detection rates for BORN rose by 30% after training.
News
FDA approves combo Lonsurf for gastric and GEJ adenocarcinomas
FDA approval was based on a boost in overall survival demonstrated in the phase 3 TAGS trial.
From the Journals
Meta-analysis generally supports LI-RADS classification accuracy
But 13% of lesions classified as probably benign (LI-RADS2) were actually hepatocellular carcinomas.
From the Journals
Obesity-related cancers increasing in younger adults
Half of obesity-related cancers have increased in incidence among younger adults over the past two decades.
Conference Coverage
Cancer vaccine fails in CRC but trial yields lessons
SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...
Conference Coverage
mRECIST response to kinase inhibitors predicts survival in HCC
SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...